Cited by 1,357RNA Interference and Gene DeliveryVirus-based gene therapy researchRNA Research and Splicing

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

RNAi-mediated gene silencing in non-human primates

Zimmermann, Tracy S., Lee, Amy C. H., Akinc, Akin, Bramlage, Birgit, Bumcrot, David, Fedoruk, Matthew N., Harborth, Jens, Heyes, James A., Jeffs, Lloyd B., John, Matthias, Judge, Adam D., Lam, Kieu, McClintock, Kevin, Nechev, Lubomir V., Palmer, Lorne R., Racie, Timothy, Röhl, Ingo, Seiffert, Stephan, Shanmugam, Sumi, Sood, Vandana, Soutschek, Jürgen, Toudjarska, Ivanka, Wheat, Amanda J., Yaworski, Ed, Zedalis, William, Koteliansky, Victor, Manoharan, Muthiah, Vornlocher, Hans-Peter, MacLachlan, Ian·2006·Nature

DOI 10.1038/nature04688

Open this paper in CoChat — free account

Abstract

The opportunity to harness the RNA interference (RNAi) pathway to silence disease-causing genes holds great promise for the development of therapeutics directed against targets that are otherwise not addressable with current medicines. Although there are numerous examples of in vivo silencing of target genes after local delivery of small interfering RNAs (siRNAs), there remain only a few reports of RNAi-mediated silencing in response to systemic delivery of siRNA, and there are no reports of systemic efficacy in non-rodent species. Here we show that siRNAs, when delivered systemically in a liposomal formulation, can silence the disease target apolipoprotein B (ApoB) in non-human primates. APOB-specific siRNAs were encapsulated in stable nucleic acid lipid particles (SNALP) and administered by intravenous injection to cynomolgus monkeys at doses of 1 or 2.5 mg kg(-1). A single siRNA injection resulted in dose-dependent silencing of APOB messenger RNA expression in the liver 48 h after administration, with maximal silencing of >90%. This silencing effect occurred as a result of APOB mRNA cleavage at precisely the site predicted for the RNAi mechanism. Significant reductions in ApoB protein, serum cholesterol and low-density lipoprotein levels were observed as early as 24 h after treatment and lasted for 11 days at the highest siRNA dose, thus demonstrating an immediate, potent and lasting biological effect of siRNA treatment. Our findings show clinically relevant RNAi-mediated gene silencing in non-human primates, supporting RNAi therapeutics as a potential new class of drugs.

Integrity signals

Registry

Crossref · 10.1038/nature04688

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,206
Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7
Hornung, V., Guenthner‐Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A. M., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,261
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,260
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K. S., Jensen, K., Breen, W., Hartsough, K. C., Machemer, L., Radka, S. F., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,175
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,027
The RNAi revolution
Novina, C. D., & Sharp, P. A. (2004) · Nature · doi:10.1038/430161a · Cited by 739
Inhibition of respiratory viruses by nasally administered siRNA
Bitko, V., Musiyenko, A., Shulyayeva, O., & Barik, S. (2004) · Nature Medicine · doi:10.1038/nm1164 · Cited by 731

Flagged first, then by citations

Show all 20 references

Sorted by citations

Items 401–500 of 1,001

Fluorinated Oligoethylenimine Nanoassemblies for Efficient siRNA-Mediated Gene Silencing in Serum-Containing Media by Effective Endosomal Escape
Zhang, T., Huang, Y., Ma, X., Gong, N., Liu, X., Liu, L., Ye, X., Hu, B., Li, C., Tian, J., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02553 · Cited by 80
From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies
Adachi, H., Hengesbach, M., Yu, Y., & Morais, P. (2021) · Biomedicines · doi:10.3390/biomedicines9050550 · Cited by 84
“showed that ionizable cationic LNPs (known as Sta‐ ble Nucleic Acid‐Lipid Particles, or SNALPs) could successfully deliver siRNAs systemi‐ cally in non‐human primates [59].”
Background
Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics
Semple, S. C., Leone, R. D., Barbosa, C., Tam, Y. K., & Lin, P. J. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020398 · Cited by 80
“In 2006, the first successful demonstration of systemically delivered siRNA using a LNP to down-regulate gene expression in non-human primates (NHP) was reported, knocking down serum apolipoprotein B (ApoB) levels [51].”
Background
Efficient Gene Silencing in Lungs and Liver Using Imidazole-Modified Chitosan As a Nanocarrier for Small Interfering RNA
Ghosn, B., Singh, A. K., Li, M., Vlassov, A. V., Burnett, C., Puri, N., & Roy, K. (2010) · Oligonucleotides · doi:10.1089/oli.2010.0235 · Cited by 80
Factors influencing the separation of oligonucleotides using reversed-phase/ion-exchange mixed-mode high performance liquid chromatography columns
Biba, M., Jiang, E., Mao, B., Zewge, D., Foley, J. P., & Welch, C. J. (2013) · Journal of Chromatography A · doi:10.1016/j.chroma.2013.06.050 · Cited by 80
MicroRNA-like off-target transcript regulation by siRNAs is species specific
Burchard, J., Jackson, A. L., Malkov, V. A., Needham, R. H. V., Tan, Y., Bartz, S. R., Dai, H. A., Sachs, A. B., & Linsley, P. S. (2009) · RNA · doi:10.1261/rna.1326809 · Cited by 81
Intracellular Delivery of RNA-based Therapeutics Using Aptamers
Thiel, K. W., & Giangrande, P. H. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.61 · Cited by 78
Transthyretin Cardiac Amyloidoses in Older North Americans
Dharmarajan, K., & Maurer, M. S. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03868.x · Cited by 80
“In this manner, siRNAs are being produced to selectively target the mutant TTR gene.(59) Similarly, antisense nucleotides have been designed that specifically bind to mRNA transcripts of the TTR gene.”
Background
Design and Creation of New Nanomaterials for Therapeutic RNAi
Baigude, H., McCarroll, J. A., Yang, C., Swain, P. M., & Rana, T. M. (2007) · ACS Chemical Biology · doi:10.1021/cb7000582 · Cited by 80
The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice
Hatakeyama, H., Murata, M., Sato, Y., Takahashi, M. M., Minakawa, N., Matsuda, A., & Harashima, H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.10.023 · Cited by 78
Recent Progress in Chemically Modified siRNAs
Gaglione, M., & Messere, A. (2010) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955710791384036 · Cited by 76
“SiRNA formulations include electrostatic complexes of siRNA with cationic lipids (lipoplex) or polycations (polyplex) [151-153], lipopolyplexes [154-156], liposomes encapsulating siRNA [157].”
Background
siRNA‐based nanotherapeutics as emerging modalities for immune‐mediated diseases: A preliminary review
Sargazi, S., Arshad, R., Ghamari, R., Rahdar, A., Bakhshi, A., Fathi‐karkan, S., Ajalli, N., Bilal, M., & Diez-Pascual, A. M. (2022) · Cell Biology International · doi:10.1002/cbin.11841 · Cited by 77
Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer
McCarroll, J. A., Teo, J., Boyer, C. A., Goldstein, D., Kavallaris, M., & Phillips, P. A. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00002 · Cited by 77
“The therapeutic potential of nanoparticle-siRNA complexes to treat human disease was first reported by Zimmermann et al. (2006).”
BackgroundInfluential
The versatility of oligonucleotides as potential therapeutics
Eckstein, F. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.7.1021 · Cited by 77
Comparison of chitosan/siRNA and trimethylchitosan/siRNA complexes behaviour in vitro
Dehousse, V., Garbacki, N., Jaspart, S., Castagne, D., Piel, G., Colige, A., & Évrard, B. (2010) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2010.01.010 · Cited by 76
Covalent Strategies for Targeting Messenger and Non-Coding RNAs: An Updated Review on siRNA, miRNA and antimiR Conjugates
Grijalvo, S., Alagia, A., Jorge, A. F., & Eritja, R. (2018) · Genes · doi:10.3390/genes9020074 · Cited by 79
“SNALP and iNOP platforms are part of these technologies which are based on lipid-based systems and generally used as vehicles for improving the delivery of siRNA molecules into the liver [107,108].”
Background
Design of Cationic Multiwalled Carbon Nanotubes as Efficient siRNA Vectors for Lung Cancer Xenograft Eradication
Guo, C., Al-Jamal, W. T., Toma, F. M., Bianco, A., Prato, M., Al‐Jamal, K. T., & Kostarelos, K. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00249 · Cited by 76
High-Density Lipoprotein Facilitates In Vivo Delivery of α-Tocopherol–Conjugated Short-Interfering RNA to the Brain
Uno, Y., Piao, W., Miyata, K., Nishina, K., Mizusawa, H., & Yokota, T. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.083 · Cited by 76
“Much progress has been reported on intravenous administration of siRNA to the liver using cationic liposomes, nanoparticles, and cellpenetrating peptides (Zimmermann et al., 2006; Moschos et al., 2007; Rozema et al., 2007; Wolfrum et al., 2007; Akinc et al., 2008, 2009; Gao et al., 2009).”
Background
Metabolomics of prolonged fasting in humans reveals new catabolic markers
Rubio‐Aliaga, I., de Roos, B., Duthie, S. J., Crosley, L. K., Mayer, C., Horgan, G. W., Colquhoun, I. J., Gall, G. L., Huber, F., Kremer, W., et al. (2010) · Metabolomics · doi:10.1007/s11306-010-0255-2 · Cited by 75
Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes
Hossain, S., Stanislaus, A., Chua, M. J., Tada, S., Tagawa, Y., Chowdhury, E. H., & Akaike, T. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.06.024 · Cited by 75
Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia
Liu, S. Q., Tefft, B. J., Roberts, D., Zhang, L., Ren, Y., Li, Y. C., Huang, Y., Zhang, D., Phillips, H. R., & Wu, Y. H. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00362.2012 · Cited by 78
Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery
Merzouki, A., Alameh, M., DeJesus, D., Jean, M., Darras, V., Thibault, M., Lavertu, M., & Buschmann, M. D. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s26571 · Cited by 80
“Intravenous injection of stable nucleic acid-lipid particles has successfully targeted the liver to silence the apolipoprotein B (ApoB) gene in mice and nonhuman primates.(10) However, a significant 20-fold transient elevation in serum transaminases (aspartate transaminase, alanine transaminase) indicative of hepatoce…”
Harnessing a Physiologic Mechanism for siRNA Delivery With Mimetic Lipoprotein Particles
Nakayama, T., Butler, J. S., Sehgal, A., Severgnini, M., Racie, T., Sharman, J., Ding, F., Shulga‐Morskaya, S., Brodsky, J., Tchangov, L., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.33 · Cited by 75
siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids
Tadin‐Strapps, M., Peterson, L. B., Cumiskey, A.-M., Rosa, R. L., Mendoza, V., Castro‐Perez, J. M., Puig, Ó., Zhang, L., Strapps, W. R., Yendluri, S., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m012872 · Cited by 77
Neuroblastoma-targeted Nanoparticles Entrapping siRNA Specifically Knockdown ALK
Paolo, D. D., Brignole, C., Pastorino, F., Carosio, R., Zorzoli, A., Rossi, M., Loi, M., Pagnan, G., Emionite, L., Cilli, M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.54 · Cited by 74
Concepts in in vivo siRNA delivery for cancer therapy
Gondi, C. S., & Rao, J. S. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21790 · Cited by 73
“One of the most important advances in the development of RNAi as a therapeutic came with the demonstration that systemically delivered siRNA in a stable nucleic acid–lipid form targeting ApoB was able to silence ApoB in mice and non-human primates (Zimmermann et al., 2006).”
Background
Acidification-Induced Structure Evolution of Lipid Nanoparticles Correlates with Their In Vitro Gene Transfections
Li, Z., Carter, J., Santos, L., Webster, C. I., van der Walle, C. F., Li, P., Rogers, S. E., & Lu, J. R. (2023) · ACS Nano · doi:10.1021/acsnano.2c06213 · Cited by 76
RETRACTED: Nano-scale delivery systems for siRNA delivery in cancer therapy: New era of gene therapy empowered by nanotechnology
Ebrahimi, N., Manavi, M. S., Nazari, A., Momayezi, A., Faghihkhorasani, F., Abdulwahid, A. R. R., Rezaei‐Tazangi, F., Kavei, M., Rezaei, R., Mobarak, H., et al. (2023) · Environmental Research · doi:10.1016/j.envres.2023.117263 · Cited by 75
Retracted
Preparation of small amounts of sterile siRNA-liposomes with high entrapping efficiency by dual asymmetric centrifugation (DAC)
Hirsch, M., Ziroli, V., Helm, M., & Massing, U. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.11.029 · Cited by 73
Mechanistically Probing Lipid-siRNA Nanoparticle-associated Toxicities Identifies Jak Inhibitors Effective in Mitigating Multifaceted Toxic Responses
Tao, W., Mao, X., Davide, J. P., Ng, B., Cai, M., Burke, P. A., Sachs, A. B., & Sepp‐Lorenzino, L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.282 · Cited by 73
Glycosaminoglycans in the cellular uptake of drug delivery vectors – Bystanders or active players?
Favretto, M. E., Wallbrecher, R., Schmidt, S., van de Putte, R., & Brock, R. E. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.02.011 · Cited by 78
Combinatorial Approach to Determine Functional Group Effects on Lipidoid-Mediated siRNA Delivery
Mahon, K. P., Love, K. T., Whitehead, K. A., Qin, J., Akinc, A., Leshchiner, E. S., Leshchiner, I., Langer, R., & Anderson, D. G. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100041r · Cited by 73
“Indeed, a recent report indicates successful siRNA delivery to primates using such methods (10).”
Background
Glycerol Monooleate-Based Nanocarriers for siRNA Delivery in Vitro
Zhen, G., Hinton, T. M., Muir, B. W., Shi, S., Tizard, M. L., McLean, K. M., Hartley, P. G., & Gunatillake, P. A. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200662f · Cited by 73
Systemic RNAi in Caenorhabditis elegansPreprint
Hunter, C. P., Winston, W. M., Molodowitch, C., Feinberg, E. H., Shih, J. D., Sutherlin, M. E., Wright, A. J., & Fitzgerald, M. (2006) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2006.71.060 · Cited by 73
In Vivo Delivery Aspects of miRNA, shRNA and siRNA
Khatri, N., Rathi, M. N., Baradia, D., Trehan, S., & Misra, A. R. (2012) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v29.i6.20 · Cited by 69
Microfluidics: a transformational tool for nanomedicine development and production
Garg, S., Heuck, G., Ip, S. Y., & Ramsay, E. (2016) · Journal of drug targeting · doi:10.1080/1061186x.2016.1198354 · Cited by 76
“were able to reduce the particle size to around 80 nm and increase the encapsulation to about 95% by using a higher concentration of cationic lipid and lower concentration of DSPC, which, respectively, were believed to increase interaction with siRNA and favor smaller electron-dense nanostructures [32,38].”
BackgroundMethod
Development of a Novel Method for Formulating Stable siRNA-Loaded Lipid Particles for In vivo Use
Wu, S. Y., Tom, L. N., Liang, M., Chang, H.-I., Davies, N. M., & McMillan, N. A. J. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9766-1 · Cited by 71
Targeting glucose uptake with siRNA-based nanomedicine for cancer therapy
Xu, C., Liu, Y., Shen, S., Zhu, Y., & Wang, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.01.068 · Cited by 71
Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response
Lee, Y.-H., Judge, A., Seo, D., Kitade, M., Gómez-Quiroz, L. E., Ishikawa, T., Andersen, J. B., Kim, B.-K., Marquardt, J. U., Raggi, C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.126 · Cited by 73
“…liver as well as solid tumors and have demonstrated robust therapeutic silencing of endogenous hepatocyte, tumor or viral gene transcripts in the absence of any measurable immune response (Jeffs et al., 2005; Morrissey and Blanchard et al., 2005; Zimmermann et al., 2006; Judge et al., 2009).”
Background
Definition of Ubiquitination Modulator COP1 as a Novel Therapeutic Target in Human Hepatocellular Carcinoma
Lee, Y.-H., Andersen, J. B., Song, H., Judge, A. D., Seo, D., Ishikawa, T., Marquardt, J. U., Kitade, M., Durkin, M. E., Raggi, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0749 · Cited by 71
Lipid-based nanoparticles for cancer treatment
Obeid, M. A., Tate, R. J., Mullen, A. B., & Ferro, V. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813687-4.00008-6 · Cited by 74
Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum
Hoerter, J. A. H., & Walter, N. G. (2007) · RNA · doi:10.1261/rna.602307 · Cited by 71
Non-viral gene therapy for neurological diseases, with an emphasis on targeted gene delivery
Rogers, M., & Rush, R. A. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.026 · Cited by 70
“down regulated in monkeys using specific siRNAs encapsulated in stable nucleic acid lipid particles (SNALP) [49].”
Background
Doxorubicin-loaded micelles in tumor cell-specific chemotherapy
Almajidi, Y. Q., Kadhim, M. M., Alsaikhan, F., Jalil, A. T., Sayyid, N. H., Ramírez‐Coronel, A. A., Jawhar, Z. H., Gupta, J., Nabavi, N., Yu, W., et al. (2023) · Environmental Research · doi:10.1016/j.envres.2023.115722 · Cited by 73
Reversal of Lung Cancer Multidrug Resistance by pH-Responsive Micelleplexes Mediating Co-Delivery of siRNA and Paclitaxel
Yu, H., Xu, Z., Chen, X., Xu, L., Yin, Q., Zhang, Z., & Li, Y. (2013) · Macromolecular Bioscience · doi:10.1002/mabi.201300282 · Cited by 70
Efficient Biodistribution and Gene Silencing in the Lung epithelium via Intravenous Liposomal Delivery of siRNA
McCaskill, J. L., Singhania, R., Burgess, M. L., Allavena, R., Wu, S. Y., Blumenthal, A., & McMillan, N. A. J. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.22 · Cited by 70
Nanotubes Functionalized with Lipids and Natural Amino Acid Dendrimers: A New Strategy to Create Nanomaterials for Delivering Systemic RNAi
McCarroll, J. A., Baigude, H., Yang, C., & Rana, T. M. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900296z · Cited by 70
Lipid Nanoparticles: A Novel Gene Delivery Technique for Clinical Application
Mashima, R., & Takada, S. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100341 · Cited by 73
“Among various liver disorders, familial hypercholesterolemia (FH) is a genetic disorder involving multiple genes, such as LDLR, ApoB, and Pcsk9 [39].”
Background
Identification of siRNA delivery enhancers by a chemical library screen
Gilleron, J., Paramasivam, P., Zeigerer, A., Querbes, W., Marsico, G., Andree, C., Seifert, S., Amaya, P., Stöter, M., Koteliansky, V., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv762 · Cited by 71
Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles
Yu, H., Zou, Y., Jiang, L., Yin, Q., He, X., Chen, L., Zhang, Z., Gu, W., & Li, Y. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.12.042 · Cited by 69
Mechanism of Macromolecular Structure Evolution in Self-Assembled Lipid Nanoparticles for siRNA Delivery
Gindy, M. E., DiFelice, K., Kumar, V., Prud’homme, R. K., Celano, R., Haas, R. M., Smith, J. S., & Boardman, D. (2014) · Langmuir · doi:10.1021/la500630h · Cited by 70
Inorganic nanoparticle-based advanced cancer therapies: Promising combination strategies
Amaldoss, M. J. N., Yang, J., Koshy, P., Unnikrishnan, A., & Sorrell, C. C. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103386 · Cited by 68
A multifunctional and reversibly polymerizable carrier for efficient siRNA delivery
Wang, X.-L., Nguyen, T. D., Gillespie, D. L., Jensen, R. L., & Lu, Z. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.08.048 · Cited by 68
Genetics and molecular pathology of Stargardt-like macular degeneration
Vasireddy, V., WONG, P. W. K., & Ayyagari, R. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.01.001 · Cited by 68
“Inhibition of mutant gene expression can be achieved by a variety of approaches, including antisense, ribozymes, and, more recently, RNA interference (RNAi) (Hauswirth et al., 2000; LaVail et al., 2000; Bumcrot et al., 2006; Zimmermann et al., 2006).”
Background
Aerosol delivery of stabilized polyester-siRNA nanoparticles to silence gene expression in orthotopic lung tumors
Yan, Y., Zhou, K., Xiong, H., Miller, J. B., Motea, E. A., Boothman, D. A., Liu, L., & Siegwart, D. J. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.12.001 · Cited by 68
“efficacious for gene silencing in the liver [7-11].”
Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery
Chen, Q., Butler, D., Querbes, W., Pandey, R. K., Ge, P., Maier, M. A., Zhang, L., Rajeev, K. G., Nechev, L. V., Koteliansky, V., et al. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.02.011 · Cited by 68
Lipid Nanoparticles for Cell-Specific in Vivo Targeted Delivery of Nucleic Acids
Khalil, I. A., Younis, M. A., Kimura, S., & Harashima, H. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00743 · Cited by 68
Nanocarriers for Delivery of siRNA and Co-Delivery of siRNA and Other Therapeutic Agents
Zhao, J., & Feng, S. (2015) · Nanomedicine · doi:10.2217/nnm.15.61 · Cited by 72
β-Catenin Small Interfering RNA Successfully Suppressed Progression of Multiple Myeloma in a Mouse Model
Ashihara, E., Kawata, E., Nakagawa, Y., Shimazaski, C., Kuroda, J., Taniguchi, K., Uchiyama, H., Tanaka, R., Yokota, A., Takeuchi, M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1350 · Cited by 67
Advances in systemic siRNA delivery
Leng, Q., Woodle, M. C., Lu, P. Y., & Mixson, A. J. (2009) · Drugs of the Future · doi:10.1358/dof.2009.034.09.1413267 · Cited by 74
Protein disulfide isomerases contribute differentially to the endoplasmic reticulum–associated degradation of apolipoprotein B and other substrates
Grubb, S. R., Guo, L., Fisher, E. A. A., & Brodsky, J. L. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-08-0704 · Cited by 68
MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model
Boekhorst, B. C. M. T., Jensen, L., Colombo, S., Varkouhi, A. K., Schiffelers, R. M., Lammers, T., Storm, G., Nielsen, H. M., Strijkers, G. J., Foged, C., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.004 · Cited by 66
Targeted Treatment of Cancer with Nanotherapeutics Based on Mesoporous Silica Nanoparticles
Knežević, N. Ž., & Durand, J. (2015) · ChemPlusChem · doi:10.1002/cplu.201402369 · Cited by 65
Silencing microRNA by interfering nanoparticles in mice
Su, J., Baigude, H., McCarroll, J. A., & Rana, T. M. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1307 · Cited by 65
Antisense Technology: An Emerging Platform for Cardiovascular Disease Therapeutics
Lee, R. G., Crosby, J. R., Baker, B. F., Graham, M. J., & Crooke, R. M. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9495-7 · Cited by 66
“In addition to mipomersen, both siRNA and LNA oligonucleotides targeting apoB mRNA have been studied [54, 55].”
Background
Development of pH–responsive nanocarriers using trimethylchitosans and methacrylic acid copolymer for siRNA delivery
Dehousse, V., Garbacki, N., Colige, A., & Évrard, B. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.028 · Cited by 65
Challenges and Opportunities for Local and Systemic Delivery of siRNA and Antisense Oligonucleotides
Sepp‐Lorenzino, L., & Ruddy, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.174 · Cited by 65
Recent advances on nanoparticle-based therapies for cardiovascular diseases
Soumya, R. S., & Raghu, K. G. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.02.009 · Cited by 68
A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics
Ranjbar, S., Zhong, X., Manautou, J. E., & Lü, X. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115052 · Cited by 66
Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells
Meyer, C., Eydeler, K., Magbanua, E., Živković, T., Piganeau, N., Lorenzen, I., Grötzinger, J., Mayer, G., Rose‐John, S., & Hahn, U. (2012) · RNA Biology · doi:10.4161/rna.9.1.18062 · Cited by 64
“Non-covalent assemblies include the encapsulation of siRNAs into lipid particles.(36) Covalent conjugation was also successfully performed for siRNAs and lipids, like cholesterol.”
Background
Cell penetrating peptide-mediated systemic siRNA delivery to the liver
Hayashi, Y., Yamauchi, J., Khalil, I. A., Kajimoto, K., Akita, H., & Harashima, H. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.038 · Cited by 66
Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates
Suzuki, Y., Hyodo, K., Suzuki, T., Tanaka, Y., Kikuchi, H., & Ishihara, H. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.01.016 · Cited by 64
Therapeutic RNA Delivery for COVID and Other Diseases
Dobrowolski, C. N., Paunovska, K., Hatit, M. Z. C., Lokugamage, M. P., & Dahlman, J. E. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002022 · Cited by 62
Advances in RNA-based therapeutics: current breakthroughs, clinical translation, and future perspectives
Makkar, S. K. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1675209 · Cited by 72
A rapid, targeted, neuron-selective, in vivo knockdown following a single intracerebroventricular injection of a novel chemically modified siRNA in the adult rat brain
Nakajima, H., Kubo, T., Semi, Y., Itakura, M., Kuwamura, M., Izawa, T., Azuma, Y., & Takeuchi, T. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.10.003 · Cited by 64
Physicochemical characterization techniques for lipid based delivery systems for siRNA
Kapoor, M., Burgess, D. J., & Patil, S. D. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.09.032 · Cited by 64
Cell and Tissue Targeting of Nucleic Acids for Cancer Gene Therapy
Ruß, V., & Wagner, E. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9233-9 · Cited by 63
Effective siRNA delivery and target mRNA degradation using an amphipathic peptide to facilitate pH-dependent endosomal escape
Bartz, R., Fan, H., Zhang, J., Innocent, N., Cherrin, C., Beck, S. C., Pei, Y., Momose, A., Jadhav, V., Tellers, D. M., et al. (2011) · Biochemical Journal · doi:10.1042/bj20101021 · Cited by 63
A peptidomimetic siRNA transfection reagent for highly effective gene silencing
Konca, Y. U., Dehan, E., Ouerfelli, O., Piano, F., Zuckermann, R. N., Pagano, M., & Kirshenbaum, K. (2006) · Molecular BioSystems · doi:10.1039/b603229j · Cited by 63
Expressing short hairpin RNAs in vivo
Snøve, O., & Rossi, J. J. (2006) · Nature Methods · doi:10.1038/nmeth927 · Cited by 64
Discovery of siRNA Lipid Nanoparticles to Transfect Suspension Leukemia Cells and Provide In Vivo Delivery Capability
He, W., Bennett, M. J., Luistro, L. L., Carvajal, D. M., Nevins, T. D., Smith, M., Tyagi, G., Cai, J. J., Wei, X. L., Lin, T.-A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.210 · Cited by 62
Formulation of Small Activating RNA Into Lipidoid Nanoparticles Inhibits Xenograft Prostate Tumor Growth by Inducing p21 Expression
Place, R. F., Wang, J., Noonan, E. J., Meyers, R. E., Manoharan, M., Charissé, K., Duncan, R., Huang, V., Wang, X., & Li, L. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.5 · Cited by 62
Combinatorial optimization of PEG architecture and hydrophobic content improves ternary siRNA polyplex stability, pharmacokinetics, and potency in vivo
Werfel, T. A., Jackson, M. A., Kavanaugh, T. E., Kirkbride, K. C., Miteva, M., Giorgio, T. D., & Duvall, C. L. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.389 · Cited by 61
“To date, a variety of methodologies have been developed to overcome the challenge of siRNA delivery, including covalent modifications [5,6], antibody-protamine fusion [7], liposomal encapsulation [8], and nanoparticle formulations of cationic lipids or polymers [9–11].”
Surveillance of siRNA integrity by FRET imaging
Järve, A., Müller, J., Kim, I.-H., Rohr, K., MacLean, C., Fricker, G., Massing, U., Eberle, F., Dalpke, A. H., Fischer, R., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm694 · Cited by 62
BARRIERS TO SUCCESSFUL DELIVERY OF SHORT INTERFERING RNA AFTER SYSTEMIC ADMINISTRATION
White, P. J. (2008) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.04992.x · Cited by 61
“is reached or approached in a number of studies, including those involving low mg/kg doses and low volume injection.(59,60) In addi-”
Background
Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing
Youssef, M., Hitti, C., Fulber, J. P. C., & Kamen, A. (2023) · Biomolecules · doi:10.3390/biom13101497 · Cited by 63
“Further progress was achieved when another class of lipid-based nanocarriers, lipid nanoparticles (LNPs), were efﬁcient in RNA delivery in non-human primates [190,191].”
Background
Strategies to use microRNAs as therapeutic targets
Krützfeldt, J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.07.004 · Cited by 62
Medicinal Chemistry of siRNA Delivery
Stanton, M. G., & Colletti, S. L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1003914 · Cited by 60
Adsorption and Release of siRNA from Porous Silica
Steinbacher, J. L., & Landry, C. C. (2013) · Langmuir · doi:10.1021/la402850m · Cited by 61
Lipid‐Like Nanomaterials for Simultaneous Gene Expression and Silencing In Vivo
Dong, Y., Eltoukhy, A. A., Alabi, C. A., Khan, O. F., Omid Veiseh, A., Dorkin, J. R., Sirirungruang, S., Yin, H., Tang, B. C., Pelet, J. M., et al. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201400054 · Cited by 60
Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions
Ezzat, K., Zaghloul, E. M., Andaloussi, S. E., Lehto, T., El-Sayed, R., Magdy, T., Smith, C. I. E., & Langel, Ü. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.006 · Cited by 60
“The new generation of lipid-based siRNA vectors like SNALPs [25] and Lipidoids [26] has probably overcome some of these limitations; however, the complex multicomponent nature of such systems could limit them from being widely used.”
Background
Bioanalysis of siRNA and Oligonucleotide Therapeutics in Biological Fluids and Tissues
Tremblay, G. A., & Oldfield, P. R. (2009) · Bioanalysis · doi:10.4155/bio.09.66 · Cited by 61
Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro
Broering, R., Real, C. I., John, M., Jahn‐Hofmann, K., Ickenstein, L. M., Kleinehr, K., Paul, A., Sutter, K., Dittmer, U., Gerken, G., et al. (2013) · International Immunology · doi:10.1093/intimm/dxt040 · Cited by 60
Dicetyl Phosphate-Tetraethylenepentamine-Based Liposomes for Systemic siRNA Delivery
Asai, T., Matsushita, S., Kenjo, E., Tsuzuku, T., Yonenaga, N., Koide, H., Hatanaka, K., Dewa, T., Nango, M., Maeda, N., et al. (2011) · Bioconjugate Chemistry · doi:10.1021/bc1004697 · Cited by 60
Nanoplumbers: biomaterials to fight cardiovascular diseases
Dormont, F., Varna, M., & Couvreur, P. (2017) · Materials Today · doi:10.1016/j.mattod.2017.07.008 · Cited by 61
Aptamers as Drug Delivery Vehicles
Kruspe, S., Mittelberger, F., Szameit, K., & Hahn, U. (2014) · ChemMedChem · doi:10.1002/cmdc.201402163 · Cited by 59
Principles of lipid nanoparticle design for mRNA delivery
Zhang, Y., Zhang, X., Gao, Y., & Liu, S. (2024) · BMEMat · doi:10.1002/bmm2.12116 · Cited by 62
Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer
Kawata, E., Ashihara, E., Kimura, S. H., Takenaka, K., Sato, K., Tanaka, R., Yokota, A., Kamitsuji, Y., Takeuchi, M., Kuroda, J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0473 · Cited by 59
In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR)
Landesman, Y., Svrzikapa, N., Cognetta, A. B., Zhang, X., Bettencourt, B. R., Kuchimanchi, S., Dufault, K., Shaikh, S., Gioia, M., Akinc, A., et al. (2010) · Silence · doi:10.1186/1758-907x-1-16 · Cited by 59
“LNPs impose an additional barrier to quantification as the siRNA must be efficiently liberated from the particles before quantification.”
Influential
Engineered nanoparticles for systemic siRNA delivery to malignant brain tumours
Karlsson, J. E., Rui, Y., Kozielski, K., Placone, A. L., Choi, O., Tzeng, S. Y., Kim, J., Keyes, J. J., Bogorad, M. I., Gabrielson, K. L., et al. (2019) · Nanoscale · doi:10.1039/c9nr04795f · Cited by 60

Authors: Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., Judge, A. D., Lam, K., McClintock, K., Nechev, L. V., Palmer, L. R., Racie, T., Röhl, I., Seiffert, S., Shanmugam, S., Sood, V., Soutschek, J., Toudjarska, I., Wheat, A. J., Yaworski, E., Zedalis, W., Koteliansky, V., Manoharan, M., Vornlocher, H.-P., & MacLachlan, I.
Affiliations: Alnylam Pharmaceuticals (United States) (US)
Electronic Arts (Canada) (CA)
Corresponding author: Zimmermann, Tracy S.
MacLachlan, Ian
ORCID: Lee, Amy C. H.
Fedoruk, Matthew N.
Harborth, Jens
Heyes, James A.
Lam, Kieu
McClintock, Kevin
Palmer, Lorne R.
Manoharan, Muthiah
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2006-03-26
Volume: 441
Issue: 7089
Pages: 111-114
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature04688
OpenAlex: W2095151181
Cited by: 1,357
References: 20
Citations by year: 2026: 21 · 2025: 22 · 2024: 30 · 2023: 42 · 2022: 40 · 2021: 35 · 2020: 35 · 2019: 46 · 2018: 30 · 2017: 47 · 2016: 54 · 2015: 70 · 2014: 97 · 2013: 113 · 2012: 111
FWCI: 46.06
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Alnylam Pharmaceuticals
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords: RNA interference, gene silencing, siRNA, apolipoprotein B, siRNA therapeutics, systemic siRNA delivery, Macaca fascicularis, non-human primates, hypercholesterolemia, LDL cholesterol, B-cell lymphoma, CARD11
MeSH terms: Animals, Apolipoproteins B, Phenotype, Primates, RNA, Messenger, RNA Interference, RNA, Small Interfering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

RNAi-mediated gene silencing in non-human primates

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks